Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nervgen Pharma Corp (NGEN)

Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 46,920 K
  • Annual Income, $ -38,100 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 0.00
  • Price/Book 0.00
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on 11/24/25
  • Next Earnings Date 12/31/69
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Options Overview Details

View History
  • Implied Volatility 51.21% (-361.36%)
  • Historical Volatility 62.01%
  • IV Percentile 3%
  • IV Rank 3.62%
  • IV High 920.90% on 02/12/26
  • IV Low 18.59% on 02/17/26
  • Expected Move (DTE 21) 0.26 (6.97%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 78
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 392
  • Open Int (30-Day) 389
  • Expected Range 3.41 to 3.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.55 +3.10%
on 03/13/26
4.39 -16.63%
on 03/04/26
-0.52 (-12.44%)
since 02/26/26
3-Month
3.55 +3.10%
on 03/13/26
6.30 -41.90%
on 01/08/26
-1.75 (-32.32%)
since 12/26/25
52-Week
1.50 +144.00%
on 06/02/25
6.30 -41.90%
on 01/08/26
+1.81 (+97.84%)
since 03/26/25

Most Recent Stories

More News
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN” No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading...

NGEN : 3.66 (-6.39%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma to Participate at Upcoming Investor Conferences

VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence,...

NGEN : 3.66 (-6.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Begins Trading on Nasdaq Today

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.150 (+3.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.